COR Therapeutics Betters Estimate

COR Therapeutics ( CORR) posted a first-quarter loss of 5 cents a share, a penny better than analysts had expected.

In the year-earlier period, the biotech posted a loss of 19 cents a share. Revenue climbed 27% to $22.8 million from $17.9 million.

The company also again said it expects to earn 35 cents to 37 cents a share this year. Analysts expect that it'll earn 34 cents a share, according to Thomson Financial/First Call.

More from Investing

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Complying With GDPR Could Be Costly for Facebook, Google and Other Tech Giants

Complying With GDPR Could Be Costly for Facebook, Google and Other Tech Giants

Experts Break Down GDPR Risks for Investors

Experts Break Down GDPR Risks for Investors

60 Seconds: What the Heck is GDPR?

60 Seconds: What the Heck is GDPR?

Market Can't Handle the Wild Ride: Cramer's 'Mad Money' Recap (Thursday 5/24/18)

Market Can't Handle the Wild Ride: Cramer's 'Mad Money' Recap (Thursday 5/24/18)